PharmaLundensis is a research company. The company's main focus is on the treatment of serious lung diseases. Diseases that the company specializes in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced pulmonary failure. In addition to its main business, technical systems for handling drug emissions are developed. PharmaLundensis has its headquarters in Lund.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Staffan Skogvall | 43,88 | 43,88 | 2025-10-01 |
| Vict Th Engwalls Stiftelse | 5,21 | 5,21 | 2025-09-26 |
| Arne Arvidsson | 1,89 | 1,89 | 2025-09-26 |
| Arne Skogvall | 1,86 | 1,86 | 2025-09-26 |
| Tommy Johansson | 0,96 | 0,96 | 2025-09-26 |
| Nordnet Pensionsförsäkring | 0,95 | 0,95 | 2025-09-26 |
| Monica Billgert | 0,84 | 0,84 | 2025-09-26 |
| Avanza Pension | 0,83 | 0,83 | 2025-09-26 |
| Investment Aktiebolaget Balticum | 0,77 | 0,77 | 2025-09-26 |
| Staffan Engelbert Bodén | 0,59 | 0,59 | 2025-09-26 |
2026-02-19 Year End Report 2025
